BSESupha Pharmachem LtdHighNeutral
Announced Tue, 12 May · 15:08 IST

Appointment of Resolution Professional in place of Interim Resolution Professional

Nclt Insolvency AdmittedRegulatory & Legal View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
1-day move
₹0.42
prior close
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-4.8-16.7-33.3-23.8
Up moveDown movePending
AI summary

Supha Pharmachem Limited, currently under Corporate Insolvency Resolution Process (CIRP), has received NCLT approval to appoint Mr. Raju Mangilal Marshiya as the Resolution Professional, replacing the Interim Resolution Professional. The NCLT Mumbai Bench passed the order on April 30, 2026, based on a resolution passed by the Committee of Creditors (CoC) with 67.28% voting share. The CoC consists of Operational Creditors as there are no Financial Creditors in this case. Mr. Raju Mangilal Marshiya has taken over the conduct of CIRP, and the powers of the Board of Directors remain suspended. The company was admitted to CIRP based on a petition filed by Operational Creditor Boston Ivy Healthcare Solutions Private Limited under Section 9 of the Insolvency and Bankruptcy Code, 2016.

Likely market impact

The replacement of the IRP with a permanent RP indicates the insolvency resolution process is progressing. The stock remains suspended from trading, and shareholders should expect continued uncertainty until a resolution plan is approved or the company faces liquidation.